Amicus Therapeutics, Inc.
FOLDUnited States
43 filed reports · 524 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $634MFY2025 · to Dec 31, 2025+20.0% from $528M10-K | $169MQ3 FY2025 · to Sep 30, 2025+19.5% from $142M10-Q |
| Net income | -$27.1MFY2025 · to Dec 31, 2025a year earlier: -$56.1M10-K | $17.3MQ3 FY2025 · to Sep 30, 2025a year earlier: -$6.73M10-Q |
| Operating income | $32.8MFY2025 · to Dec 31, 2025+31.8% from $24.9M10-K | $34.3MQ3 FY2025 · to Sep 30, 2025+58.2% from $21.7M10-Q |
Filed reports
43 reports · Jun 2015 to Dec 2025Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 32 | 4,288 | Jun 2015 to Sep 2025 |
| Annual · 10-KSEC EDGAR | 10 | 4,430 | Dec 2015 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 316 | Dec 2016 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2025 | 10-K | Dec 31, 2025 | Feb 20, 2026 | 926 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 213 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 31, 2025 | 199 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 1, 2025 | 207 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 19, 2025 | 425 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 143 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 139 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 146 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 28, 2024 | 428 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 8, 2023 | 146 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Aug 8, 2023 | 138 | Open |
| FY2023 Q1 | 10-Q | Mar 31, 2023 | May 10, 2023 | 141 | Open |
Financial data
524 concepts · 9,034 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial517 concepts · 8,886 facts · Nov 2013 to Dec 2025
- Allocated share based compensation expense61 · Dec 2013 to Dec 2025
- Cash and cash equivalents at carrying value61 · Dec 2013 to Dec 2025
- Comprehensive income net of tax61 · Dec 2013 to Dec 2025
- Investment income interest61 · Dec 2013 to Dec 2025
- Net income loss61 · Dec 2013 to Dec 2025
- Operating expenses (US GAAP)61 · Dec 2013 to Dec 2025
- Operating income loss61 · Dec 2013 to Dec 2025
- Other comprehensive income loss net of tax portion attributable to parent61 · Dec 2013 to Dec 2025
- Research and development expense excluding acquired in process cost61 · Dec 2013 to Dec 2025
- Other nonoperating income expense60 · Mar 2014 to Dec 2025
- Antidilutive securities excluded from computation of earnings per share amount59 · Dec 2013 to Dec 2025
- Common stock par or stated value per share59 · Nov 2014 to Dec 2025
- Increase decrease in accounts payable and accrued liabilities59 · Dec 2013 to Dec 2025
- Increase decrease in prepaid deferred expense and other assets59 · Dec 2013 to Dec 2025
- Other comprehensive income availableforsale securities adjustment net of tax portion attributable to parent59 · Dec 2013 to Dec 2025
- Payments to acquire property plant and equipment59 · Dec 2013 to Dec 2025
- Proceeds from sale and maturity of available for sale securities59 · Dec 2013 to Dec 2025
- Share based compensation59 · Dec 2013 to Dec 2025
- Proceeds from stock options exercised58 · Sep 2014 to Dec 2025
- Stockholders equity (US GAAP)58 · Dec 2013 to Dec 2025
- Accumulated depreciation depletion and amortization property plant and equipment56 · Dec 2014 to Dec 2025
- Additional paid in capital common stock56 · Dec 2014 to Dec 2025
- Assets56 · Dec 2014 to Dec 2025
- Assets current56 · Dec 2014 to Dec 2025
Product6 concepts · 82 facts · Jun 2016 to Dec 2025
- Revenue75 · Jun 2016 to Dec 2025
- Impairment of long lived assets held for use2 · Dec 2017
- Income tax expense benefit2 · Sep 2017 to Dec 2017
- Fair value measurement with unobservable inputs reconciliation recurring basis liability gain loss included in earnings1 · Sep 2017
- Research and development expenses due to wind-down1 · Sep 2017
- Selling , General and Administrative Costs Due to Wind-down1 · Sep 2017
Geography1 concept · 66 facts · Mar 2018 to Sep 2024
- Revenue66 · Mar 2018 to Sep 2024
Segments
148 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis2 members · 72 facts
- Galafold36 · Dec 2022 to Dec 2025
- Pombiliti + Opfolda36 · Dec 2022 to Dec 2025
Statement geographical2 members · 66 facts
- Ex-U.S.33 · Mar 2018 to Sep 2024
- U.S.33 · Mar 2018 to Sep 2024
Product or serviceus-gaap:ProductOrServiceAxis2 members · 10 facts
- SD-1017 · Sep 2017 to Dec 2017
- Galafold3 · Jun 2016 to Mar 2017
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of Amicus Therapeutics, Inc. (FOLD) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.